Chemical Genomics Centre, Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany; Max Planck Institute for Neurological Research with Klaus-Joachim- Zülch, Laboratories of the Max Planck Society and the Medical Faculty, University of Köln, Gleueler Strasse 50, 50931 Köln, Germany; Department i of Internal Medicine, Center of Integrated Oncology Köln - Bonn, University of Köln, 50924 Köln, Germany; Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa
Pawar, V.G., Chemical Genomics Centre, Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany; Sos, M.L., Max Planck Institute for Neurological Research with Klaus-Joachim- Zülch, Laboratories of the Max Planck Society and the Medical Faculty, University of Köln, Gleueler Strasse 50, 50931 Köln, Germany; Rode, H.B., Chemical Genomics Centre, Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany; Rabiller, M., Chemical Genomics Centre, Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany; Heynck, S., Max Planck Institute for Neurological Research with Klaus-Joachim- Zülch, Laboratories of the Max Planck Society and the Medical Faculty, University of Köln, Gleueler Strasse 50, 50931 Köln, Germany; Van Otterlo, W.A.L., Chemical Genomics Centre, Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany, Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg, South Africa; Thomas, R.K., Chemical Genomics Centre, Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany, Max Planck Institute for Neurological Research with Klaus-Joachim- Zülch, Laboratories of the Max Planck Society and the Medical Faculty, University of Köln, Gleueler Strasse 50, 50931 Köln, Germany, Department i of Internal Medicine, Center of Integrated Oncology Köln - Bonn, University of Köln, 50924 Köln, Germany; Rauh, D., Chemical Genomics Centre, Max Planck Society, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany
epidermal growth factor receptor; erlotinib; n (3 ethynylphenyl) 6,7 bis(2 methoxyethoxy)quinolin 4 amine; n (3 ethynylphenyl) 6,7 dimethoxyquinazolin 4 amine; n (3 ethynylphenyl) 6,7 dimethoxyquinolin 4 amine; n [4 (3 bromophenylamino)quinazoline 6 yl]acrylamide; n [4 (3 bromophenylamino)quinazoline 6 yl]propionamide; n [4 (3 bromophenylamino)quinolin 6 yl] 4 (dimethylamino)butanamide; n [4 (3 bromophenylamino)quinolin 6 yl]acrylamide; n [4 (3 bromophenylamino)quinolin 6 yl]propionamide; n [4 [(3 bromo phenyl)amino]quinazoline 6 yl]4 (dimethylamino)butanamide; quinoline derivative; unclassified drug; article; drug activity; drug synthesis; human; lung small cell cancer; structure activity relation; substitution reaction; Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Protein Kinase Inhibitors; Quinolines; Receptor, Epidermal Growth Factor; Structure-Activity Relationship